Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Bevacizumab Biosimilars Market Size Shifted, And What Is the Outlook Through 2034?
The market size for bevacizumab biosimilars has demonstrated robust growth in recent years. With an expected compound annual growth rate (CAGR) of 7.2%, this market is projected to increase from $1.53 billion in 2024 to $1.64 billion in 2025. Factors contributing to this growth during the historical period include patent expiration, healthcare cost containment, a rising prevalence of cancer, market competitiveness, patient affordability and access, as well as the acceptance of biosimilars.
The market size for bevacizumab biosimilars is projected to experience robust growth in the upcoming years, reaching approximately $2.23 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%. Factors contributing to this potential growth during the forecast period are an increased need for cancer treatments, expertise in the development of biosimilars, strains on the healthcare system, the regulatory environment for biosimilars, and biosimilar interchangeability. Key trends forecasted for the period include partnerships and collaborative efforts, regulatory progress and approvals, innovations in biosimilar development, strategies for obtaining market access, and the management of the biosimilar lifecycle.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp
Which Primay Drivers Are Accelerating Growth in the Bevacizumab Biosimilars Market?
The anticipated rise in cancer cases is set to significantly boost the bevacizumab biosimilar market. The term ‘cancer incidence’ denotes the quantity of new cancer cases within a certain population over a specific timeframe. Bevacizumab, a biologic, helps inhibit tumor angiogenesis, potentially leading to the shrinkage of tumors and stifling their growth. It’s worth noting that it is on par with reference biologics in terms of efficacy and safety when treating patients suffering from advanced non-small cell lung cancer or metastatic colorectal cancer. For instance, in October 2024, the UK’s National Health Service (NHS) reported 346,217 new cases of cancer in 2022, translating to an average of 948 new diagnoses each day. This marks a 5% increase compared to 329,664 cases reported in 2021. Additionally, 2022 registered a 7% spike in cancer diagnoses, rising from 167,917 to 180,877. Hence, the augmenting prevalence of cancer conditions fuels the growth of the bevacizumab biosimilars market.
Which Primary Segments of the Bevacizumab Biosimilars Market Are Driving Growth and Industry Transformations?
The bevacizumab biosimilars market covered in this report is segmented –
1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer
Subsegments:
1) By Avastin: Original Avastin Product
2) By Mvasi: Mvasi (Amgen Biosimilar)
3) By Zirabev: Zirabev (Pfizer Biosimilar)
4) By Aybintio: Aybintio (Samsung Bioepis Biosimilar)
5) By Other Products: Additional Bevacizumab Biosimilars
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=10848&type=smp
Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Bevacizumab Biosimilars Market?# Market?
North America was the largest region in the bevacizumab biosimilars market in 2024. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Technological Trends Are Reshaping the Bevacizumab Biosimilars Industry Dynamics?
A significant trend that’s gaining traction in the bevacizumab biosimilars market is product innovation. Top contenders in the market are currently focusing on constructing innovative products to enhance their market status. For example, in May 2022, pharmaceutical companies, Viatris and Biocon Biologics, both based in the US, introduced a biosimilar named Abevmy, mirroring Roche’s Avastin (bevacizumab). Health Canada has approved Abevmy for use in four distinct oncology applications. The product is described as disbursing efficiency, safety, and quality on par with the reference biologic, given that it’s a humanized monoclonal antibody (MA) designed to attach to and neutralize the biologic response of human vascular endothelial growth factor (VEGF).
View the full report here:
https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report
What Parameters Are Used to Define the Bevacizumab Biosimilars Market?
Bevacizumab biosimilars are a type of medication that is highly similar to a reference biologic drug called bevacizumab. It is commonly used to inhibit the growth of new blood vessels in tumors, thereby slowing down their progression.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10848
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
